Oral Corticosteroid Improves Walking Ability in Patients with Refractory Lumbar Spinal Stenosis .
A short-term oral corticosteroid for refractory lumbar spinal stenosis: a double-blinded randomized placebo-controlled clinical trial
Int J Rehabil Res. 2020 Dec;43(4):342-346.Ninety-three patients with refractory lumbar spinal stenosis (LSS) were randomized to receive 1 week of oral corticosteroid (prednisolone; n=47) or a placebo (n=46) for the improvement of functionality and relief of pain. The primary outcomes of interest was the improvement in walking distance and Oswestry Disability Index (ODI). The secondary outcomes of interest was pain score on a Numeric Rating Scale (NRS). Outcomes were assessed 2 months post-treatment. Moreover, NRS pain scores, walking distance, and ODI scores were statistically significantly in favour of the corticosteroid group compared to the placebo group (p=0.01 for all). However, only walking distance showed statistically significant improvements from baseline values, in the corticosteroid group vs placebo (p<0.0001).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
